Skip to main content
Top
Published in: Journal of Gastrointestinal Surgery 2/2011

01-02-2011 | Original Article

A Nationwide Analysis of Changes in Severity and Outcomes of Inflammatory Bowel Disease Hospitalizations

Authors: Ashwin N. Ananthakrishnan, Emily L. McGinley, David G. Binion, Kia Saeian

Published in: Journal of Gastrointestinal Surgery | Issue 2/2011

Login to get access

Abstract

Introduction

The past decade has seen a change in inflammatory bowel disease (IBD; Crohn's disease (CD) and ulcerative colitis (UC)) treatment, with increasing use of immunomodulators and biologics. The impact of this on IBD hospitalization outcomes is unknown.

Methods

We identified hospitalizations with a diagnosis of IBD using data from the Nationwide Inpatient Sample, a national US discharge database. We compared the proportion of hospitalizations resulting in surgery in the entire cohort and within each disease severity stratum for the years 1998, 2004, and 2007.

Results

There were an estimated 89,673 hospitalizations for CD in 1998 increasing to 150,593 hospitalizations in 2007. UC hospitalizations increased from 56,911 in 1998 to 86,611 in 2007. This increase was primarily among low or intermediate severity hospitalizations not requiring surgery. For CD, the proportion of bowel surgeries during hospitalization decreased from 17.3% in 1998 to 12.4% in 2007 (p < 0.001) while for UC, the proportion of colectomy decreased from 9.5% in 1998 to 6.2% in 2007 (p < 0.001). For both diagnoses, this reduction was significant in those with a low severity of disease but not with in those with the highest severity stratum.

Conclusions

There continues to be an increase in the number of hospitalizations in patients with IBD. The numbers of non-elective bowel surgeries among those with the highest severity of disease continues to increase suggesting need for further research into improving outcomes in this cohort at high risk for adverse outcome.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. Dec 2008;135(6):1907–1913.CrossRefPubMed Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. Dec 2008;135(6):1907–1913.CrossRefPubMed
2.
go back to reference Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. May 4 2002;359(9317):1541–1549.CrossRefPubMed Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. May 4 2002;359(9317):1541–1549.CrossRefPubMed
3.
go back to reference Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. Feb 26 2004;350(9):876–885.CrossRefPubMed Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. Feb 26 2004;350(9):876–885.CrossRefPubMed
4.
go back to reference Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. Oct 9 1997;337(15):1029–1035.CrossRefPubMed Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. Oct 9 1997;337(15):1029–1035.CrossRefPubMed
5.
go back to reference Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. Jan 2007;132(1):52–65.CrossRefPubMed Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. Jan 2007;132(1):52–65.CrossRefPubMed
6.
go back to reference Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. Nov 2008;135(5):1493–1499.CrossRefPubMed Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. Nov 2008;135(5):1493–1499.CrossRefPubMed
7.
go back to reference Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. Jun 19 2007;146(12):829–838.PubMed Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. Jun 19 2007;146(12):829–838.PubMed
8.
go back to reference Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. Jul 19 2007;357(3):239–250.CrossRefPubMed Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. Jul 19 2007;357(3):239–250.CrossRefPubMed
9.
go back to reference Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. Nov 3 2005;353(18):1912–1925.CrossRefPubMed Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. Nov 3 2005;353(18):1912–1925.CrossRefPubMed
10.
go back to reference Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. Dec 8 2005;353(23):2462–2476.CrossRefPubMed Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. Dec 8 2005;353(23):2462–2476.CrossRefPubMed
11.
go back to reference Ananthakrishnan AN, McGinley EL, Binion DG, Saeian K. A novel risk score to stratify severity of Crohn’s disease hospitalizations. Am J Gastroenterol. 2010;(in press). Ananthakrishnan AN, McGinley EL, Binion DG, Saeian K. A novel risk score to stratify severity of Crohn’s disease hospitalizations. Am J Gastroenterol. 2010;(in press).
12.
go back to reference Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. Feb 2005;54(2):237–241.CrossRefPubMed Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. Feb 2005;54(2):237–241.CrossRefPubMed
13.
go back to reference Bewtra M, Su C, Lewis JD. Trends in hospitalization rates for inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol. May 2007;5(5):597–601.CrossRefPubMed Bewtra M, Su C, Lewis JD. Trends in hospitalization rates for inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol. May 2007;5(5):597–601.CrossRefPubMed
14.
go back to reference Cannom RR, Kaiser AM, Ault GT, Beart RW, Jr., Etzioni DA. Inflammatory bowel disease in the United States from 1998 to 2005: has infliximab affected surgical rates? Am Surg. Oct 2009;75(10):976–980.PubMed Cannom RR, Kaiser AM, Ault GT, Beart RW, Jr., Etzioni DA. Inflammatory bowel disease in the United States from 1998 to 2005: has infliximab affected surgical rates? Am Surg. Oct 2009;75(10):976–980.PubMed
15.
go back to reference Nguyen GC, Tuskey A, Dassopoulos T, Harris ML, Brant SR. Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004. Inflamm Bowel Dis. Dec 2007;13(12):1529–1535.CrossRefPubMed Nguyen GC, Tuskey A, Dassopoulos T, Harris ML, Brant SR. Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004. Inflamm Bowel Dis. Dec 2007;13(12):1529–1535.CrossRefPubMed
16.
go back to reference Odes S. How expensive is inflammatory bowel disease? A critical analysis. World J Gastroenterol. Nov 21 2008;14(43):6641–6647.CrossRefPubMed Odes S. How expensive is inflammatory bowel disease? A critical analysis. World J Gastroenterol. Nov 21 2008;14(43):6641–6647.CrossRefPubMed
19.
go back to reference Ananthakrishnan AN, McGinley EL, Binion DG. Does it matter where you are hospitalized for inflammatory bowel disease? A nationwide analysis of hospital volume. Am J Gastroenterol. Nov 2008;103(11):2789–2798.CrossRefPubMed Ananthakrishnan AN, McGinley EL, Binion DG. Does it matter where you are hospitalized for inflammatory bowel disease? A nationwide analysis of hospital volume. Am J Gastroenterol. Nov 2008;103(11):2789–2798.CrossRefPubMed
20.
go back to reference Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. Jan 1998;36(1):8–27.CrossRefPubMed Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. Jan 1998;36(1):8–27.CrossRefPubMed
21.
go back to reference Ananthakrishnan AN, McGinley EL, Binion DG, Saeian K. A simple risk score to identify colectomy risk in Ulcerative Colitis hospitalizations. Inflamm Bowel Dis. 2009;(in press). Ananthakrishnan AN, McGinley EL, Binion DG, Saeian K. A simple risk score to identify colectomy risk in Ulcerative Colitis hospitalizations. Inflamm Bowel Dis. 2009;(in press).
22.
go back to reference Bernstein CN, Nabalamba A. Hospitalization, surgery, and readmission rates of IBD in Canada: a population-based study. Am J Gastroenterol. Jan 2006;101(1):110–118.CrossRefPubMed Bernstein CN, Nabalamba A. Hospitalization, surgery, and readmission rates of IBD in Canada: a population-based study. Am J Gastroenterol. Jan 2006;101(1):110–118.CrossRefPubMed
23.
go back to reference Bernstein CN, Nabalamba A. Hospitalization-based major comorbidity of inflammatory bowel disease in Canada. Can J Gastroenterol. Aug 2007;21(8):507–511.PubMed Bernstein CN, Nabalamba A. Hospitalization-based major comorbidity of inflammatory bowel disease in Canada. Can J Gastroenterol. Aug 2007;21(8):507–511.PubMed
24.
go back to reference Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. Apr 2007;13(4):481–489.CrossRefPubMed Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. Apr 2007;13(4):481–489.CrossRefPubMed
25.
go back to reference Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. Apr 2005;128(4):862–869.CrossRefPubMed Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. Apr 2005;128(4):862–869.CrossRefPubMed
26.
go back to reference Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol. Aug 2002;35(2):151–156.CrossRefPubMed Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol. Aug 2002;35(2):151–156.CrossRefPubMed
27.
go back to reference Picco MF, Zubiaurre I, Adluni M, Cangemi JR, Shelton D. Immunomodulators are associated with a lower risk of first surgery among patients with non-penetrating non-stricturing Crohn's disease. Am J Gastroenterol. Nov 2009;104(11):2754–2759.CrossRefPubMed Picco MF, Zubiaurre I, Adluni M, Cangemi JR, Shelton D. Immunomodulators are associated with a lower risk of first surgery among patients with non-penetrating non-stricturing Crohn's disease. Am J Gastroenterol. Nov 2009;104(11):2754–2759.CrossRefPubMed
28.
go back to reference Punati J, Markowitz J, Lerer T, et al. Effect of early immunomodulator use in moderate to severe pediatric Crohn disease. Inflamm Bowel Dis. Jul 2008;14(7):949–954.CrossRefPubMed Punati J, Markowitz J, Lerer T, et al. Effect of early immunomodulator use in moderate to severe pediatric Crohn disease. Inflamm Bowel Dis. Jul 2008;14(7):949–954.CrossRefPubMed
29.
go back to reference Bojic D, Radojicic Z, Nedeljkovic-Protic M, Al-Ali M, Jewell DP, Travis SP. Long-term outcome after admission for acute severe ulcerative colitis in Oxford: the 1992–1993 cohort. Inflamm Bowel Dis. Jun 2009;15(6):823–828.CrossRefPubMed Bojic D, Radojicic Z, Nedeljkovic-Protic M, Al-Ali M, Jewell DP, Travis SP. Long-term outcome after admission for acute severe ulcerative colitis in Oxford: the 1992–1993 cohort. Inflamm Bowel Dis. Jun 2009;15(6):823–828.CrossRefPubMed
30.
go back to reference Aratari A, Papi C, Clemente V, et al. Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liver Dis. Oct 2008;40(10):821–826.CrossRefPubMed Aratari A, Papi C, Clemente V, et al. Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liver Dis. Oct 2008;40(10):821–826.CrossRefPubMed
31.
go back to reference Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. Jun 2005;128(7):1805–1811.CrossRefPubMed Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. Jun 2005;128(7):1805–1811.CrossRefPubMed
32.
go back to reference Regueiro M, Curtis J, Plevy S. Infliximab for hospitalized patients with severe ulcerative colitis. J Clin Gastroenterol. Jul 2006;40(6):476–481.CrossRefPubMed Regueiro M, Curtis J, Plevy S. Infliximab for hospitalized patients with severe ulcerative colitis. J Clin Gastroenterol. Jul 2006;40(6):476–481.CrossRefPubMed
Metadata
Title
A Nationwide Analysis of Changes in Severity and Outcomes of Inflammatory Bowel Disease Hospitalizations
Authors
Ashwin N. Ananthakrishnan
Emily L. McGinley
David G. Binion
Kia Saeian
Publication date
01-02-2011
Publisher
Springer-Verlag
Published in
Journal of Gastrointestinal Surgery / Issue 2/2011
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-010-1396-3

Other articles of this Issue 2/2011

Journal of Gastrointestinal Surgery 2/2011 Go to the issue